| Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore PG Ambrose, SM Bhavnani, CM Rubino, A Louie, T Gumbo, A Forrest, ... Clinical Infectious Diseases 44 (1), 79-86, 2007 | 798 | 2007 |
| Antimicrobial treatment guidelines for acute bacterial rhinosinusitis SAH Partnership Otolaryngology--Head and Neck Surgery 130 (1_suppl), 1-45, 2004 | 635* | 2004 |
| Antimicrobial safety: focus on fluoroquinolones RC Owens Jr, PG Ambrose Clinical infectious diseases 41 (Supplement_2), S144-S157, 2005 | 610 | 2005 |
| Voriconazole therapeutic drug monitoring J Smith, N Safdar, V Knasinski, W Simmons, SM Bhavnani, PG Ambrose, ... Antimicrobial agents and chemotherapy 50 (4), 1570-1572, 2006 | 497 | 2006 |
| Pharmacodynamics of Fluoroquinolones againstStreptococcus pneumoniae in Patients with Community-Acquired Respiratory Tract Infections PG Ambrose, DM Grasela, TH Grasela, J Passarell, HB Mayer, PF Pierce Antimicrobial agents and chemotherapy 45 (10), 2793-2797, 2001 | 404 | 2001 |
| Extended-spectrum β-lactamases and clinical outcomes: current data R Ramphal, PGA > Clinical infectious diseases 42 (Supplement_4), S164-S172, 2006 | 399 | 2006 |
| Back to the future: using aminoglycosides again and how to dose them optimally GM Eliopoulos, GL Drusano, PG Ambrose, SM Bhavnani, JS Bertino, ... Clinical infectious diseases 45 (6), 753-760, 2007 | 304 | 2007 |
| Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis SM Bhavnani, CM Rubino, PG Ambrose, GL Drusano Clinical infectious diseases 50 (12), 1568-1574, 2010 | 264 | 2010 |
| Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective JW Mouton, PG Ambrose, R Canton, GL Drusano, S Harbarth, ... Drug Resistance Updates 14 (2), 107-117, 2011 | 249 | 2011 |
| The pharmacokinetic and pharmacodynamic profile of tigecycline AK Meagher, PG Ambrose, TH Grasela, JE Grosse Clinical infectious diseases 41 (Supplement_5), S333-S340, 2005 | 214 | 2005 |
| Clinical use of the fluoroquinolones RC Owens Jr, PG Ambrose Medical Clinics of North America 84 (6), 1447-1469, 2000 | 212 | 2000 |
| Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations T Gumbo, A Louie, W Liu, D Brown, PG Ambrose, SM Bhavnani, ... Antimicrobial agents and chemotherapy 51 (7), 2329-2336, 2007 | 196 | 2007 |
| Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis GE Thwaites, SM Bhavnani, TTH Chau, JP Hammel, ME Török, ... Antimicrobial agents and chemotherapy 55 (7), 3244-3253, 2011 | 171 | 2011 |
| Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem SM Bhavnani, JP Hammel, BB Cirincione, MA Wikler, PG Ambrose Antimicrobial agents and chemotherapy 49 (9), 3944-3947, 2005 | 160 | 2005 |
| Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent AK Meagher, PG Ambrose, TH Grasela, EJ Ellis-Grosse Diagnostic microbiology and infectious disease 52 (3), 165-171, 2005 | 156 | 2005 |
| The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae PG Ambrose, DM Grasela Diagnostic microbiology and infectious disease 38 (3), 151-157, 2000 | 149 | 2000 |
| Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I … MN Dudley, PG Ambrose, SM Bhavnani, WA Craig, MJ Ferraro, RN Jones, ... Clinical infectious diseases 56 (9), 1301-1309, 2013 | 147 | 2013 |
| Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap! PG Ambrose, SM Bhavnani, EJE Grosse, GL Drusano Clinical infectious diseases 51 (Supplement_1), S103-S110, 2010 | 139 | 2010 |
| Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended … PG Ambrose, SM Bhavnani, RN Jones Antimicrobial agents and chemotherapy 47 (5), 1643-1646, 2003 | 137 | 2003 |
| Torsades de pointes associated with fluoroquinolones. RC Owens Jr, PG Ambrose Pharmacotherapy 22 (5), 663-8; discussion 668, 2002 | 137 | 2002 |
